Sponsored session – Boys, men and HPV: the case for worldwide gender-neutral vaccination

Room 8 (level 0)
Sponsored session

Information

Session organised by Global Action on Men's Health, MSD, NOMAN is and Island: Race to end HPV

Chaired by David Winterflood, NOMAN: Race to End HPV (United Kingdom)

Presentations:

1. The case for global gender-neutral HPV vaccination - Peter Baker, Global Action on Men's Health (United Kingdom)

2. Panel discussion - Bettina Borisch, World Federation of Public Health Associations (Switzerland)

3. Panel discussion - Tristan Almada, NOMAN is an Island: Race to End HPV (Switzerland)

4. Panel discussion - Ibtihal Fadhil, Eastern Mediterranean NCD Alliance (United Arab Emirates)

5. Panel discussion - Richard Price, Europe Cancer Organization (ECO) (Belgium)

Theme
1. Prevention, screening and early detection
Objectives
Human papillomavirus (HPV) is responsible for 5% of all cancers globally, including cervical, anal, penile, vaginal, vulval, and head and neck cancers affecting both men and women. Vaccination against HPV offers the opportunity to prevent these cancers. However, current vaccination programmes in many countries, particularly in low- and middle-income regions, target girls, neglecting boys. This approach does not provide comprehensive and equitable protection for everyone. To address this gap, a Global Call for Action "Boys, Men and HPV: A Manifesto for Gender-Neutral Vaccination", will be launched at the World Cancer Congress by Global Action on Men’s Health and NOMAN is an Island: Race to End HPV. The Manifesto aims to generate awareness of the role of gender-neutral (or universal) vaccination (GNV) and advocate for a policy re-think at the global level. GNV will create more effective protection against all HPV-related cancers and reduce their global burden thereby safeguarding global health.
MSDFor more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Log in

See all the content and easy-to-use features by logging in or registering!